Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
Authors:
- on behalf of the Colon Cancer Study GroupOGon behalf of the Colon Cancer Study Group
- José Luis CallejaJCJosé Luis Calleja
Open Access
- 22 December 2015
- journal article
- research article
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 31 (3) , 543-551
Abstract
Purpose The purpose of the study was to evaluate the efficacy of preoperative intravenous (IV) ferric carboxymaltose (FCM) administration vs. no-IV iron in colon cancer (CC) anemic patients undergoing elective surgery with curative intention. Methods This was a multicenter, observational study including two cohorts of consecutive CC anemic patients: the no-IV iron treatment group was obtained retrospectively while FCM-treated patients were recorded prospectively. Results A total of 266 patients were included: 111 received FCM (median dose 1000 mg) and 155 were no-IV iron subjects. Both groups were similar in terms of demographic characteristics, tumor location, surgical approach, and intra-operative bleeding severity. The FCM group showed a significant lower need for red blood cell (RBC) transfusion during the study (9.9 vs. 38.7 %; OR: 5.9, p < 0.001). In spite of lower hemoglobin levels at baseline diagnosis and lower transfusion rates in the FCM group, the proportion of responders was significantly higher with respect to the no-IV group both at hospital admission (48.1 vs. 20.0 %, p < 0.0001) and at 30 days post-surgery (80.0 vs. 48.9 %, p < 0.0001). The percentage of patients with normalized hemoglobin levels was also higher in the FCM group (40.0 vs. 26.7 % at 30 days, p < 0.05). A lower number of reinterventions and post-surgery complications were seen in the FCM group (20.7 vs. 26.5 %; p = 0.311). The FCM group presented a significant shorter hospital stay (8.4 ± 6.8 vs. 10.9 ± 12.4 days to discharge; p < 0.001). Conclusions Preoperative ferric carboxymaltose treatment in patients with CC and iron deficiency anemia significantly reduced RBC transfusion requirements and hospital length of stay, reaching higher response rates and percentages of normalized hemoglobin levels both at hospital admission and 30 days post-surgery.Keywords
Funding Information
- Vifor Pharma España SL
This publication has 24 references indexed in Scilit:
- Effects of Preoperative Intravenous Erythropoietin Plus Iron on Outcome in Anemic Patients After Cardiac Valve ReplacementThe American Journal of Cardiology, 2012
- Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort studyThe Lancet, 2011
- Efficacy of protocol implementation based on intravenous iron treatment in gastrointestinal cancer surgeryEuropean Journal of Anaesthesiology, 2011
- Hepcidin and iron regulation, 10 years laterBlood, 2011
- Does Preoperative Anemia Adversely Affect Colon and Rectal Surgery Outcomes?Journal of the American College of Surgeons, 2011
- Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgeryBritish Journal of Surgery, 2009
- Risk Associated with Preoperative Anemia in Noncardiac SurgeryAnesthesiology, 2009
- Increased hepcidin expression in colorectal carcinogenesisWorld Journal of Gastroenterology, 2008
- External validation of a COPD diagnostic questionnaireEuropean Respiratory Journal, 2007
- Is pre-operative anaemia a risk marker for in-hospital mortality and morbidity after valve replacement?European Heart Journal, 2006